$CRSP
CRISPR Therapeutics AG · NasdaqGM · Healthcare
- Market cap
- 4.78B
- Volume
- 1.92M
- P/E
- -13.90
- Day range
- 48.02 – 49.64
- 52w range
- 44.12 – 67.73
- Analyst target
- 85.63
AI Summary
Generating a unique summary for CRSP…
AI-generated for information only — not investment advice.
Share this ticker
$CRSP -1.20% at 49.39 Cathie Wood and 0 other tracked billionaires hold it. $JNJ $NTRA $LLY https://billionairestrading.com/stocks/CRSP
Company summary
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Institutional ownership
Institutions hold 78.32% · insiders 5.97% · 678 institutions
| Holder | Shares | Value | % held | Reported |
|---|---|---|---|---|
| ARK Investment Management, LLC | 9.46M | $467.28M | 9.78% | 2026-06-30 |
| Blackrock Inc. | 8.35M | $412.36M | 8.63% | 2026-06-30 |
| Orbis Allan Gray Ltd | 5.45M | $269.13M | 5.64% | 2026-06-30 |
| Capital World Investors | 4.75M | $234.58M | 4.91% | 2026-06-30 |
| State Street Corporation | 4.32M | $213.45M | 4.47% | 2026-06-30 |
| GSK plc | 3.22M | $159.07M | 3.33% | 2026-06-30 |
| Geode Capital Management, LLC | 2.51M | $123.96M | 2.60% | 2026-06-30 |
| T. Rowe Price Investment Management, Inc. | 2.05M | $101.40M | 2.12% | 2026-06-30 |
| SR One Capital Management, LP | 2.04M | $100.69M | 2.11% | 2026-06-30 |
| Two Sigma Investments, LP | 1.99M | $98.22M | 2.06% | 2026-06-30 |
Hedge fund & billionaire activity
Insider transactions
| Insider | Role | Transaction | Shares | Date |
|---|---|---|---|---|
| KULKARNI SAMARTH | Chief Executive Officer | Sale at price 49.78 per share. | 47.8K | 2026-10-19 |
| KULKARNI SAMARTH | Chief Executive Officer | — | 100.0K | 2026-10-16 |
| KASINGER JAMES R. | General Counsel | Sale at price 60.04 per share. | 2.0K | 2026-10-06 |
| KASINGER JAMES R. | General Counsel | Conversion of Exercise of derivative security at price 13.62 per share. | 2.0K | 2026-10-06 |
| KASINGER JAMES R. | General Counsel | Sale at price 60.24 per share. | 10.4K | 2026-09-22 |
| KASINGER JAMES R. | General Counsel | Conversion of Exercise of derivative security at price 13.62 per share. | 10.4K | 2026-09-22 |
| BEHBAHANI ALI | Director | Sale at price 57.09 per share. | 13.7K | 2026-09-17 |
| BEHBAHANI ALI | Director | Conversion of Exercise of derivative security at price 14.00 per share. | 30.0K | 2026-09-17 |
| PRASAD RAJU | Chief Financial Officer | Stock Gift at price 0.00 per share. | 750.00 | 2026-08-07 |
| PATEL NAIMISH | Officer | Sale at price 55.62 per share. | 3.8K | 2026-05-29 |
| PATEL NAIMISH | Officer | — | 10.0K | 2026-05-28 |
| KULKARNI SAMARTH | Chief Executive Officer | Sale at price 46.78 per share. | 10.0K | 2026-03-23 |
Analyst ratings
Consensus score 2.04 (1 = strong buy, 5 = sell) · mean target 85.63
- UBSNeutralinit2026-10-15
- CitizensMarket Outperformreit2026-08-31
- NeedhamBuyreit2026-08-31
- CitizensMarket Outperformreit2026-08-25
- CitigroupBuymain2026-08-04
- HC Wainwright & Co.Buyreit2026-07-08
- CitizensMarket Outperformreit2026-07-06
- BernsteinMarket Performmain2026-05-13
- CitigroupBuymain2026-05-06
- Piper SandlerOverweightreit2026-03-17
Earnings
Next report: 2026-11-09
| Quarter | EPS actual | EPS estimate | Surprise |
|---|---|---|---|
| 3Q2025 | -1.17 | -1.29 | 0.12 |
| 4Q2025 | -1.37 | -1.23 | -0.14 |
| 1Q2026 | -1.28 | -1.23 | -0.05 |
| 2Q2026 | -0.94 | -1.18 | 0.24 |
SEC filings
- 8-KCorporate Changes & Voting Matters2026-10-19Open
- 8-KCorporate Changes & Voting Matters2026-08-03Open
- S-8Offering Registrations2026-06-05Open
- 8-KCorporate Changes & Voting Matters2026-06-04Open
- 10-QPeriodic Financial Reports2026-05-04Open
- ARSAnnual Report to Shareholders2026-04-21Open
- PRE 14AProxy Statements2026-04-02Open
- 8-KCorporate Changes & Voting Matters2026-03-16Open
- 8-KCorporate Changes & Voting Matters2026-03-11Open
- 10-KPeriodic Financial Reports2026-02-12Open
Latest CRSP news
- Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More
The company's gene-editing-focused platform looks promising.
Sat, 24 Oct 2026 22:20:00 +0000
- Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
Fri, 23 Oct 2026 12:00:02 +0000
- The Outlook of CRISPR Therapeutics Stock Does Not Look Strong After Its CFO Resigns
The valuation of CRSP stock is high, and its pipeline is not advanced.
Fri, 23 Oct 2026 11:14:15 +0000
- CRISPR Therapeutics AG (CRSP) Stock Moves -1.21%: What You Should Know
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $49.89, moving 1.21% from the previous trading session.
Thu, 22 Oct 2026 21:00:03 +0000
- Brokers Suggest Investing in CRISPR Therapeutics (CRSP): Read This Before Placing a Bet
The average brokerage recommendation (ABR) for CRISPR Therapeutics (CRSP) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Wed, 21 Oct 2026 12:30:03 +0000
- CRISPR Therapeutics Announces Chief Financial Officer Transition
ZUG, Switzerland and BOSTON, Oct. 19, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that its Chief Financial Officer, Raju Prasad, Ph.D., will be stepping down from the Company to pursue external opportunities, and A.J. Silver, the Company's Senior Vice President of Finance, will succeed Dr. Prasad as Chief Financial Officer. This transition will be effective today. “Raju has been a trusted partner to me and a wonderful colleague during his time at CRISPR Therapeuti
Mon, 19 Oct 2026 20:05:00 +0000
- Where Will CRISPR Therapeutics Stock Be in 2030?
The company's expertise in gene editing could lead to more breakthroughs.
Sun, 18 Oct 2026 21:33:00 +0000
- Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.
Billionaire investor Cathie Wood, through her ARK ETFs, made big buys of CRISPR Therapeutics on Friday, Oct. 9, and Monday, Oct. 12.
Sun, 18 Oct 2026 11:10:00 +0000